Cambridge University Hospitals Expands Virtual Care Program with Masimo W1™
Masimo (NASDAQ: MASI) today announced that Cambridge University Hospitals NHS Foundation Trust, U.K. is adopting the Masimo W1™ advanced health tracking watch for use in its telehealth and telemedicine programs. Masimo W1, which offers accurate, continuous measurements of key physiological parameters, is available in the UK as a medical device that integrates with the Masimo SafetyNet® remote patient management platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230507005042/en/
Masimo W1™ (Photo: Business Wire)
Joe Kiani, Founder and CEO of Masimo, said, “Masimo W1 represents not only the future of personal health but is playing a vital role in the expansion of remote healthcare. Built on our decades of expertise developing breakthrough noninvasive medical monitoring technologies, Masimo W1 is designed to aid valued hospital partners like Cambridge in accelerating their virtual hospital and telehealth programs – ultimately helping to improve patient outcomes while reducing the cost of care. We are excited for Cambridge clinicians and patients.”
Cambridge University Hospitals NHS Foundation Trust launched its virtual ward program in 2022, as part of a National Health Service (NHS) England telehealth initiative designed to promote earlier patient discharge to the home. More than 20 specialities across the hospital now participate in Cambridge’s virtual program, which sends patients home with a variety of Masimo products – such as MightySat® and wearable medical devices like Radius PPG®, Radius Tº®, and now Masimo W1 – that allow monitoring and vitals signs data to be relayed to clinicians back at the hospital. Via the Masimo SafetyNet clinician dashboard, hospital clinicians can keep an eye on their patients’ physiological status from afar, allowing patients to stay monitored in the comfort of their own homes.
Dr. Iain Goodhart, Clinical Director of the Virtual Hospital Program at Cambridge University Hospitals NHS Foundation Trust, commented, “Masimo W1 will help us expand our Virtual Hospital program by offering continuous monitoring of oxygen saturation and pulse rate, as well as ECG spot-checking, in a comfortable, easy to use watch. We hope that, integrated with Masimo SafetyNet, the telehealth platform we already use, Masimo W1 can help support more confident patient discharge and management for patients who, before our Virtual Hospital program, might have needed to stay longer in the hospital. We’re excited to incorporate Masimo W1 into our telehealth practices.”
Masimo W1 for use in medical applications is pending FDA clearance in the U.S.
@Masimo | #Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo W1™ and Masimo SafetyNet®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo W1 and Masimo SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks that Cambridge University Hospitals fails to realize the expected benefits of Masimo W1; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230507005042/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release
More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati
Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France1.6.2023 19:30:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005872/en/ Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France Carbios (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, and Indorama Ventures Public Company Limited (IVL) (Bloomberg ticker IVL.TB), a global sustainable chemical producer, announce today the signing of a non-binding Memorandum of Understanding (MOU) to form a Joint Venture for the construction of the world’s first PET biorecycling plant in France1. Based on and subject to the comprehensive terms set out in the MOU, Indorama Ventures plans to mobilize about €110 million for the Joint Venture in equity and non-convertible loan financing2, pending final engineering documentation and final economic feasibility studies. Both parties have
PPG opens Color Creation Lab with Chery Automobile in China1.6.2023 16:01:00 EEST | Press release
PPG (NYSE:PPG) today announced the opening of a Color Creation Lab in collaboration with automaker Chery Automobile Co., Ltd. At the facility, located in Wuhu, China, PPG color stylists and Chery designers will create new colors tailored to specific vehicle designs, from initial color recommendations to final materials for application in Chery’s manufacturing plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005119/en/ Representatives from PPG and Chery Automobile celebrate the opening of a Color Creation Lab in Wuhu, China. (Photo: PPG) “As the leading single-source coatings supplier for automotive manufacturing, PPG is excited to partner with Chery, a company that prioritizes technological innovation and sustainable production,” said Thomas Li, PPG vice president Asia Pacific, Automotive Coatings. “We will leverage our global color leadership to predict future trends, while advancing paint technology for the nex
HEINZ® Unveils First Global Creative Brand Platform in Over 150 Years1.6.2023 16:00:00 EEST | Press release
Today, HEINZ announces “It Has to be HEINZ,” a new global platform marking the first time in its 150-year history where the brand is unified under one creative strategy. The campaign pays homage to the brand by celebrating the irrational love people have for HEINZ – from real fans’ personal love affairs with the brand, to the love and care its products are made with. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005186/en/ HEINZ announces its first new global platform in its 150-year history “It Has to be HEINZ,” inspired by real-life stories of fans’ undeniable love of HEINZ (Graphic: Business Wire) Anchored by Kraft HEINZ’s largest media investment to date, the global creative platform demonstrates the unmatched love generations of people all over the world have for HEINZ – from Ketchup to Beanz and everything in-between(z). The fan stories featured in the creative – such as HEINZ tattoos, carrying condiment packets
PPG opens $30-million battery pack application center in China1.6.2023 16:00:00 EEST | Press release
PPG (NYSE: PPG) today announced that it has inaugurated a battery pack application center (BPAC) in Tianjin, China. The $30-million facility features a full range of capabilities to test the application of PPG coatings technologies, materials and systems for electric vehicle (EV) battery packs, allowing customers to accelerate the development of new EV technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005106/en/ PPG has inaugurated a $30-million facility in Tianjin, China to test coatings technologies, materials and systems for electric vehicle battery packs. (Photo: Business Wire) “The new application center is an important milestone in our effort to support our customers in China in the EV battery market,” said Vincent Robin, PPG global vice president, Automotive Coatings. “The new facility will be an important way for customers to validate our customizable coatings solutions that help them reduce applicat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom